Highest-materiality recent filing
Aclarion adopts one-year stockholder rights plan with 10% trigger
Board unanimously adopted Rights Plan effective March 19, 2026, expiring March 18, 2027.
Aclarion closes $10.4M equity offering, reports $21.6M cash, zero debt, runway into 2028
Closed $10.4M common-stock-only offering at $5.18/share; includes 200,000 shares and pre-funded warrants for 1.8M shares.
Aclarion raises ~$10.36M via registered direct offering of common stock and pre-funded warrants
200,000 shares at $5.18 each; pre-funded warrants for 1.8M shares at $0.00001 exercise price.
Aclarion raises ~$2.5M via registered direct offering of stock and pre-funded warrants
Issued 64,000 common shares and 236,000 pre-funded warrants at $8.36/share; gross proceeds ~$2.5M.
Aclarion appoints Greg Gould as CFO; John Lorbiecki retires
Gregory A. Gould appointed CFO effective September 1, 2025, succeeding retiring John Lorbiecki.
Cash on hand ~$14.6M as of Apr 9 2025 10-K; runway into Q3 2026; zero debt, no preferred shares, no near-term warrant overhang.
Aclarion effectuates 1-for-27 reverse stock split; shares reduce from ~15.72M to ~582K
Reverse stock split at 1-for-27 ratio effective 5:00 p.m. ET on March 27, 2025; split-adjusted trading commenced March 28.
Aclarion reports $15.2M cash, regains Nasdaq equity compliance; 87% of Series B warrants exercised
Current cash balance ~$15.2M; company in compliance with Nasdaq stockholders' equity rule of $2.5M minimum.
Aclarion prices $4.7M registered direct offering of 506,803 shares at $9.25 each
Gross proceeds ~$4.7M; 506,803 shares at $9.25/share; closing expected Jan 31, 2025.
Aclarion effects 1-for-335 reverse stock split; regains Nasdaq equity compliance
Reverse stock split effective Jan 29, 2025 at 1:335 ratio; shares reduced from ~169.4M to ~500,000.
Net proceeds of ~$13.3M from offering of 100K shares, ~144M pre-funded warrants, and Series A & B warrants.
Aclarion prices registered direct offering of 3.38M shares at $0.142/share for ~$480K gross proceeds
Pricing: 3,380,276 shares at $0.142 per share; gross proceeds ~$480,000 before fees and expenses.
Equity line expiration extended from Dec 31, 2024 to Dec 31, 2025.
Aclarion receives Nasdaq delisting notice for bid price; hearing held Oct 10
Received Oct 8 notice of non-compliance with $1 bid price requirement for Nasdaq Capital Market.
Aclarion raises $1.0M via Series C convertible preferred stock and warrants
Gross proceeds of $1.0M from sale of 1,000 shares of Series C Preferred Stock at $1,000/share, convertible at $0.1759 per share.
Aclarion stockholders approve reverse stock split of 1:5 to 1:50
Stockholders approved reverse split with 2,050,165 For, 1,133,449 Against, 583,616 Abstain.
Aclarion receives Nasdaq delisting notice for stockholders' equity shortfall
Nasdaq notified Aclarion it fails minimum $2.5M stockholders' equity requirement, reporting $1.64M as of June 30, 2024.
Aclarion exchanges $930K of near-maturing notes for Series B Preferred convertible at $0.234/share
Exchanged $930,000 of principal and accrued interest on notes due Sept 2024 for 930 Series B Preferred shares at $1,000 each.
Aclarion gets first payer coverage for Nociscan from AXA in Greater London
AXA is the 2nd largest private medical insurer in the UK with ~30% market share and ~3M insured customers.
Aclarion receives Nasdaq notice of non-compliance with minimum bid price rule
Received Nasdaq notice on April 8, 2024 for failing minimum bid price of $1.00 per share over 30 consecutive business days.
Aclarion closes $3.0M public offering; believes it regains Nasdaq equity compliance
Closed public offering of 5,175,000 units at $0.58/unit; gross proceeds ~$3.0M before expenses.
Aclarion posts $4.9M net loss in FY2023; auditor flags going concern doubt
Net loss of $4.9M in FY2023 vs $7.1M in FY2022; revenue $75,404, up 25% from $60,444.
Aclarion exchanges ~$1.19M debt for 500k shares, boosting share count to 1.79M
From Jan 23–26, 2024, Aclarion entered exchange agreements with accredited investors to swap debt for equity.
Aclarion receives Nasdaq delisting notice for equity shortfall; appeals to hearings panel
Nasdaq staff determined to delist common stock on Aug 31, 2023 for failure to meet $2.5M stockholders' equity requirement.
Aclarion closes $750K second tranche of unsecured note financing; amends terms
Received $750K gross proceeds from second tranche; principal amount $862.5K (15% OID).
Aclarion regains Nasdaq compliance after late 10-Q; auditor resigns, Haynie & Company appointed
Filed Q2 2023 Form 10-Q on Aug 25; Nasdaq confirmed compliance with Listing Rule 5250(c)(1) on Aug 28.
Aclarion receives Nasdaq notice for non-compliance with $1.00 minimum bid price requirement
Nasdaq notice dated Aug 4, 2023, due to closing bid price below $1.00 for 30 consecutive business days through Aug 3, 2023.
On June 16, 2025, John Lorbiecki notified Aclarion, Inc. of his intention to retire from his position as the Company’s Chief Financial Officer.
Max materiality 0.85 · Median 0.60 · Most common event other_material